Martos-Benítez F D, Gutiérrez-Noyola A, Badal M, Dietrich N A
Department of Intensive Care, Institute of Oncology and Radiobiology, 29 Street, Vedado, Havana, Cuba.
Department of Intensive Care, Institute of Oncology and Radiobiology, 29 Street, Vedado, Havana, Cuba.
Med Intensiva (Engl Ed). 2018 Aug-Sep;42(6):354-362. doi: 10.1016/j.medin.2017.08.004. Epub 2017 Sep 28.
To determine the risk factors for severe acute respiratory failure requiring invasive mechanical ventilation (SARF-MV) and its effect upon clinical outcomes in critically ill cancer patients.
A retrospective cohort study was carried out.
A 12-bed oncological intensive care unit (ICU) from January 2014 to December 2015.
A total of 878 consecutive cancer patients were included. Patients with an ICU stay of ≤1 day were excluded. The final sample size was 691 patients.
None.
Clinical variables at ICU admission were extracted from the medical records. The primary outcome was SARF-MV. We also measured ICU and hospital mortality, as well as length of stay.
The SARF-MV rate was 15.8%. The multivariate analysis identified brain tumour (OR 14.54; 95%CI 3.86-54.77; p<0.0001), stage IV cancer (OR 3.47; 95%CI 1.26-9.54; p=0.016), sepsis upon admission (OR 2.28; 95%CI 1.14-4.56; p=0.020) and an APACHE II score≥20 points (OR 5.38; 95%CI 1.92-15.05; p=0.001) as being independently associated to SARF-MV. Compared with the patients without SARF-MV, those with SARF-MV had a prolonged length of ICU stay (p<0.0001), a lower ICU survival rate (p<0.0001) and a lower hospital survival rate (p<0.0001).
A number of clinical factors are related to SARF-MV. In this regard, SARF-MV is a powerful factor independently correlated to poor outcomes. Future studies should investigate means for preventing SARF-MV in critically ill cancer patients, which may have an impact upon outcomes.
确定需要有创机械通气的严重急性呼吸衰竭(SARF-MV)的危险因素及其对重症癌症患者临床结局的影响。
进行一项回顾性队列研究。
2014年1月至2015年12月期间的一个拥有12张床位的肿瘤重症监护病房(ICU)。
共纳入878例连续的癌症患者。排除在ICU住院时间≤1天的患者。最终样本量为691例患者。
无。
从病历中提取ICU入院时的临床变量。主要结局是SARF-MV。我们还测量了ICU和医院死亡率以及住院时间。
SARF-MV发生率为15.8%。多变量分析确定脑肿瘤(比值比[OR]14.54;95%置信区间[CI]3.86 - 54.77;p<0.0001)、IV期癌症(OR 3.47;95%CI 1.26 - 9.54;p = 0.016)、入院时败血症(OR 2.28;95%CI 1.14 - 4.56;p = 0.020)和急性生理与慢性健康状况评分系统(APACHE)II评分≥20分(OR 5.38;95%CI 1.92 - 15.05;p = 0.001)与SARF-MV独立相关。与无SARF-MV的患者相比,有SARF-MV的患者ICU住院时间延长(p<0.0001),ICU生存率较低(p<0.0001),医院生存率较低(p<0.0001)。
一些临床因素与SARF-MV相关。在这方面,SARF-MV是一个与不良结局独立相关的有力因素。未来的研究应调查预防重症癌症患者发生SARF-MV的方法,这可能会对结局产生影响。